Novel etiological and therapeutic strategies for neurodiseases: RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis

Takuto Hideyama, Takenari Yamashita, Yoshinori Nishimoto, Takeshi Suzuki, Shin Kwak

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

The motor neurons of patients with sporadic amyotrophic lateral sclerosis (ALS) express abundant Q/R site-unedited GluR2 mRNA, whereas those of patients with other motor neuron diseases including familial ALS associated with mutated SOD1 (ALS1) and those of normal subjects express only Q/R site-edited GluR2 mRNA. Because adenosine deaminase acting on RNA type 2 (ADAR2) specifically catalyzes GluR2 Q/R site-editing, it is likely that ADAR2 activity is not sufficient to edit this site completely in motor neurons of patients with sporadic ALS. Because these molecular abnormalities occur in disease-and motor neuron-specific fashion and induce fatal epilepsy in mice, we have hypothesized that GluR2 Q/R site-underediting due to ADAR2 underactivity is a cause of neuronal death in sporadic ALS. We found that cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2) mRNA had an ADAR2-mediated editing position using RNA interference knockdown. Our review will include a discussion of new ADAR2 substrates that may be useful for research on sporadic ALS.

Original languageEnglish
Pages (from-to)9-13
Number of pages5
JournalJournal of Pharmacological Sciences
Volume113
Issue number1
DOIs
Publication statusPublished - 2010 May 17

Fingerprint

RNA Editing
Adenosine Deaminase
RNA
Enzymes
Motor Neuron Disease
Motor Neurons
Messenger RNA
Fragile X Mental Retardation Protein
Therapeutics
RNA Interference
Cause of Death
Epilepsy
Amyotrophic lateral sclerosis 1
Research
Proteins

Keywords

  • α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor
  • Amyotrophic lateral sclerosis (ALS)
  • Cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2)
  • GluR2 Q/R
  • Neurodisease
  • RNA editing

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine

Cite this

Novel etiological and therapeutic strategies for neurodiseases : RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis. / Hideyama, Takuto; Yamashita, Takenari; Nishimoto, Yoshinori; Suzuki, Takeshi; Kwak, Shin.

In: Journal of Pharmacological Sciences, Vol. 113, No. 1, 17.05.2010, p. 9-13.

Research output: Contribution to journalArticle

@article{d520f8fb0fd847e6aaf00a450e912efa,
title = "Novel etiological and therapeutic strategies for neurodiseases: RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis",
abstract = "The motor neurons of patients with sporadic amyotrophic lateral sclerosis (ALS) express abundant Q/R site-unedited GluR2 mRNA, whereas those of patients with other motor neuron diseases including familial ALS associated with mutated SOD1 (ALS1) and those of normal subjects express only Q/R site-edited GluR2 mRNA. Because adenosine deaminase acting on RNA type 2 (ADAR2) specifically catalyzes GluR2 Q/R site-editing, it is likely that ADAR2 activity is not sufficient to edit this site completely in motor neurons of patients with sporadic ALS. Because these molecular abnormalities occur in disease-and motor neuron-specific fashion and induce fatal epilepsy in mice, we have hypothesized that GluR2 Q/R site-underediting due to ADAR2 underactivity is a cause of neuronal death in sporadic ALS. We found that cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2) mRNA had an ADAR2-mediated editing position using RNA interference knockdown. Our review will include a discussion of new ADAR2 substrates that may be useful for research on sporadic ALS.",
keywords = "α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor, Amyotrophic lateral sclerosis (ALS), Cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2), GluR2 Q/R, Neurodisease, RNA editing",
author = "Takuto Hideyama and Takenari Yamashita and Yoshinori Nishimoto and Takeshi Suzuki and Shin Kwak",
year = "2010",
month = "5",
day = "17",
doi = "10.1254/jphs.09R21FM",
language = "English",
volume = "113",
pages = "9--13",
journal = "Journal of Pharmacological Sciences",
issn = "1347-8613",
publisher = "Japanese Pharmacological Society",
number = "1",

}

TY - JOUR

T1 - Novel etiological and therapeutic strategies for neurodiseases

T2 - RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis

AU - Hideyama, Takuto

AU - Yamashita, Takenari

AU - Nishimoto, Yoshinori

AU - Suzuki, Takeshi

AU - Kwak, Shin

PY - 2010/5/17

Y1 - 2010/5/17

N2 - The motor neurons of patients with sporadic amyotrophic lateral sclerosis (ALS) express abundant Q/R site-unedited GluR2 mRNA, whereas those of patients with other motor neuron diseases including familial ALS associated with mutated SOD1 (ALS1) and those of normal subjects express only Q/R site-edited GluR2 mRNA. Because adenosine deaminase acting on RNA type 2 (ADAR2) specifically catalyzes GluR2 Q/R site-editing, it is likely that ADAR2 activity is not sufficient to edit this site completely in motor neurons of patients with sporadic ALS. Because these molecular abnormalities occur in disease-and motor neuron-specific fashion and induce fatal epilepsy in mice, we have hypothesized that GluR2 Q/R site-underediting due to ADAR2 underactivity is a cause of neuronal death in sporadic ALS. We found that cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2) mRNA had an ADAR2-mediated editing position using RNA interference knockdown. Our review will include a discussion of new ADAR2 substrates that may be useful for research on sporadic ALS.

AB - The motor neurons of patients with sporadic amyotrophic lateral sclerosis (ALS) express abundant Q/R site-unedited GluR2 mRNA, whereas those of patients with other motor neuron diseases including familial ALS associated with mutated SOD1 (ALS1) and those of normal subjects express only Q/R site-edited GluR2 mRNA. Because adenosine deaminase acting on RNA type 2 (ADAR2) specifically catalyzes GluR2 Q/R site-editing, it is likely that ADAR2 activity is not sufficient to edit this site completely in motor neurons of patients with sporadic ALS. Because these molecular abnormalities occur in disease-and motor neuron-specific fashion and induce fatal epilepsy in mice, we have hypothesized that GluR2 Q/R site-underediting due to ADAR2 underactivity is a cause of neuronal death in sporadic ALS. We found that cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2) mRNA had an ADAR2-mediated editing position using RNA interference knockdown. Our review will include a discussion of new ADAR2 substrates that may be useful for research on sporadic ALS.

KW - α-amino-3-hydroxy-5-methyl-4-isoxazolepropionate (AMPA) receptor

KW - Amyotrophic lateral sclerosis (ALS)

KW - Cytoplasmic fragile X mental retardation protein interacting protein 2 (CYFIP2)

KW - GluR2 Q/R

KW - Neurodisease

KW - RNA editing

UR - http://www.scopus.com/inward/record.url?scp=77953517354&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953517354&partnerID=8YFLogxK

U2 - 10.1254/jphs.09R21FM

DO - 10.1254/jphs.09R21FM

M3 - Article

C2 - 20424386

AN - SCOPUS:77953517354

VL - 113

SP - 9

EP - 13

JO - Journal of Pharmacological Sciences

JF - Journal of Pharmacological Sciences

SN - 1347-8613

IS - 1

ER -